EA201200319A1 - Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана - Google Patents

Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана

Info

Publication number
EA201200319A1
EA201200319A1 EA201200319A EA201200319A EA201200319A1 EA 201200319 A1 EA201200319 A1 EA 201200319A1 EA 201200319 A EA201200319 A EA 201200319A EA 201200319 A EA201200319 A EA 201200319A EA 201200319 A1 EA201200319 A1 EA 201200319A1
Authority
EA
Eurasian Patent Office
Prior art keywords
overdose
etexilate
dagigatran
rendering
introduction
Prior art date
Application number
EA201200319A
Other languages
English (en)
Inventor
Джоанне Ван-Рин
Андреас Клеменс
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201200319A1 publication Critical patent/EA201200319A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к способу лечения передозировки активным веществом этексилатом дабигатрана формулы I, необязательно в форме его фармацевтически приемлемых солей, включающий введение угля в эффективном количестве.
EA201200319A 2009-08-24 2010-08-23 Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана EA201200319A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23632109P 2009-08-24 2009-08-24
PCT/EP2010/062229 WO2011023653A1 (en) 2009-08-24 2010-08-23 Emergency interventions of active charcoal with dabigatran etexilate overdosing

Publications (1)

Publication Number Publication Date
EA201200319A1 true EA201200319A1 (ru) 2012-09-28

Family

ID=42740360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200319A EA201200319A1 (ru) 2009-08-24 2010-08-23 Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана

Country Status (19)

Country Link
US (2) US20110206656A1 (ru)
EP (1) EP2470187B1 (ru)
JP (1) JP2013502449A (ru)
KR (1) KR20120050457A (ru)
CN (1) CN102481317B (ru)
AR (1) AR077909A1 (ru)
AU (1) AU2010288601A1 (ru)
BR (1) BR112012004169A2 (ru)
CA (1) CA2767966A1 (ru)
CL (1) CL2012000488A1 (ru)
DK (1) DK2470187T3 (ru)
EA (1) EA201200319A1 (ru)
ES (1) ES2436076T3 (ru)
IL (1) IL216968A0 (ru)
MX (1) MX2012001767A (ru)
NZ (1) NZ597359A (ru)
PL (1) PL2470187T3 (ru)
TW (1) TW201124143A (ru)
WO (1) WO2011023653A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
CA2827787A1 (en) * 2011-03-30 2012-10-04 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
GB201120693D0 (en) * 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
CN114452839B (zh) * 2022-02-10 2023-04-21 中南大学湘雅医院 一种抗凝抗栓血液净化膜及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5277820A (en) * 1992-02-06 1994-01-11 Hemocleanse, Inc. Device and method for extracorporeal blood treatment
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
JP3866715B2 (ja) 2002-03-07 2007-01-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル及びその塩の経口適用の投与形態

Also Published As

Publication number Publication date
WO2011023653A1 (en) 2011-03-03
US20110206656A1 (en) 2011-08-25
EP2470187A1 (en) 2012-07-04
KR20120050457A (ko) 2012-05-18
JP2013502449A (ja) 2013-01-24
DK2470187T3 (da) 2013-10-28
PL2470187T3 (pl) 2014-01-31
NZ597359A (en) 2014-01-31
CN102481317B (zh) 2014-09-03
ES2436076T3 (es) 2013-12-26
EP2470187B1 (en) 2013-08-21
IL216968A0 (en) 2012-02-29
CL2012000488A1 (es) 2012-08-31
AR077909A1 (es) 2011-09-28
US20130302311A1 (en) 2013-11-14
AU2010288601A1 (en) 2012-02-02
BR112012004169A2 (pt) 2016-03-29
MX2012001767A (es) 2012-02-29
TW201124143A (en) 2011-07-16
CA2767966A1 (en) 2011-03-03
CN102481317A (zh) 2012-05-30

Similar Documents

Publication Publication Date Title
CO6531458A2 (es) Nuevos compuestos de espiropiperidina
PH12018502731A1 (en) Treatment of cancer with dihydropyrazino-pyrazines
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
ECSP12011930A (es) Nuevos compuestos de espiropiperidina
MX2011011854A (es) Dihidropirimidinonas para uso como inhibidores de la bace2.
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
MX350745B (es) El uso de un compuesto de carbamoilo para el tratamiento del sindrome de fibromialgia.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
EA201290859A1 (ru) Лечение люпус-артрита с использованием лаквинимода
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
SG194463A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
EA201270071A1 (ru) Способ лечения пациента, нуждающегося в аспириновой терапии
EA201290603A1 (ru) Способ лечения
MX339793B (es) Metodos para tratar trastornos resistentes al metotrexato con 10-propargil-10-deaza-aminopterina.
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
EA201690327A1 (ru) Терапевтические способы
EA201200319A1 (ru) Введение активированного угля при оказании неотложной помощи в случае передозировки этексилата дабигатрана
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии
WO2013015634A3 (en) Pharmaceutical composition for treating atopic dermatitis
CL2011002444A1 (es) Composicion farmaceutica que contiene un liposoma y el compuesto activo eribulina o su sal farmacologicamente permisible en la fase interna del liposoma; y el metodo de manufactura de la composicion de liposoma.
NZ625506A (en) Compositions for treatment of heart failure in dogs.